Treatment with the fusion protein QL-1005 reduced caloric intake and body weight in mice and primates. In obese animals, it also improved insulin, fasting glucose and triglyceride levels. The design belongs to the Chinese biopharmaceutical company Beijing QL Biopharmaceutical, which will begin clinical trials in a year.
Sciwind Biosciences Co. Ltd. started dosing in a phase III clinical trial in China of its ecnoglutide (XW-003) candidate in adults with type 2 diabetes, targeting patients who have not responded adequately to either metformin or changes in lifestyle.
Novo Nordisk A/S has identified novel fatty acid modified urocortin 2 derivatives acting as CRF2 receptor agonists reported to be useful for the treatment of obesity and type 2 diabetes.
Sciwind Biosciences Co. Ltd. started dosing in a phase III clinical trial in China of its ecnoglutide (XW-003) candidate in adults with type 2 diabetes, targeting patients who have not responded adequately to either metformin or changes in lifestyle.
Metabolic health is at an odd juncture. With the advent of glucagon-like peptide (GLP-1) agonists, pharmacologically induced weight loss has matured into a viable therapeutic option at long last. GLP-1R agonists, which are also called incretin mimetics and GLP-1 analogs, are likely to continue their success across multiple areas of medical care. Already, the class has transformed diabetes care, making a splash in weight management, and it may yet do the same for other indications.
A French surgical team has performed a robot-assisted kidney auto-transplantation with ex situ tumorectomies for renal cell cancer. This is the world first use of the fourth generation Da Vinci Xi surgical robot from Sunnyvale, Calif.-based Intuitive Surgical Inc. to perform kidney explanation and autotransplantation with removal of multiple and complex tumors outside of a patient's body.
Recent work discovered several microproteins encoded by small open reading frames (smORFs) with biological functions in cell stress and survival, metabolism, and muscle development and function, among others. As an endocrine organ, the adipose tissue secretes different peptides and proteins regulating feeding, energy balance, and thermogenesis.
Cholecystokinin (CCK) is a peptide hormone found predominantly in the gastrointestinal tract and throughout the central nervous system (CNS), and which has been also shown to stimulate the secretion of calcitonin, insulin and glucagon and to act as a natriuretic kidney peptide. Researchers from Harvard University and affiliated organizations aimed to assess the function of CCK in obesity-induced airway hyperresponsiveness (AHR) and asthma.
Clearmind Medicine Inc. has released promising preclinical results demonstrating efficacy of its psychedelic-derived drug candidate MEAI for treating obesity and metabolic syndrome.
Mindrank Ltd. has received clearance of its IND application by the FDA for MDR-001, a small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which was discovered using the company’s proprietary artificial intelligence (AI) platform, Molecule Pro.
